Ann W. Gramza

Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors

Ann W. Gramza, Christopher L. Corless, Michael C. Heinrich · Clinical Cancer Research · 2009 · 225 citations · Full text

Medicine, Oncology, Pharmacology +17

Randomized Safety and Efficacy Study of Fosbretabulin with Paclitaxel/Carboplatin Against Anaplastic Thyroid Carcinoma

Julie Ann Sosa, Rossella Elisei, Barbara Jarząb et al. · Thyroid · 2013 · 151 citations

Medicine, Oncology, Pharmacology +9

Efatutazone, an Oral PPAR-γ Agonist, in Combination With Paclitaxel in Anaplastic Thyroid Cancer: Results of a Multicenter Phase 1 Trial

Robert C. Smallridge, John A. Copland, Marcia S. Brose et al. · The Journal of Clinical Endocrinology & Metabolism · 2013 · 114 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

A randomized phase II/III trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C) and paclitaxel (P) in anaplastic thyroid cancer (ATC): Final survival analysis for the FACT trial.

Julie Ann Sosa, Rossella Elisei, Barbara Jarząb et al. · Journal of Clinical Oncology · 2011 · 40 citations

Medicine, Oncology, Pharmacology +12

Updated results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine cancers (NEC).

Himisha Beltran, Melissa L. Johnson, Prantesh Jain et al. · Journal of Clinical Oncology · 2024 · 33 citations

Medicine, Oncology, Pharmacokinetics +15